<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="833">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05150314</url>
  </required_header>
  <id_info>
    <org_study_id>8426</org_study_id>
    <nct_id>NCT05150314</nct_id>
  </id_info>
  <brief_title>Comparative Study of the Hemorrhagic Risk in Patients Over 75 Years of Age Taking Enoxaparin</brief_title>
  <acronym>ENOX-VTD-H</acronym>
  <official_title>Comparative Study of the Hemorrhagic Risk in Patients Over 75 Years of Age Taking Enoxaparin at a Fixed Curative Dose of 4000 IU Twice a Day Versus at Dose / Weight Twice a Day as Part of the Treatment of Venous Thromboembolic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elderly subjects are at greater risk of thrombophlebitis than the general population, but&#xD;
      also of bleeding when anticoagulant therapy is initiated.&#xD;
&#xD;
      Enoxaparin is one of the most widely used anticoagulants in the management of venous&#xD;
      thromboembolism in the world.&#xD;
&#xD;
      Its use is not codified in the elderly, because too few studies have been carried out in&#xD;
      people over 75 years old.&#xD;
&#xD;
      For several years, Enoxaparin in curative treatment has been administered at a reduced dosage&#xD;
      of 4000 IU twice a day (and not at a standard dose of 100 IU / kg) at the Geriatrics center&#xD;
      of the CRHU in Strasbourg with the clinical impression of a reduction the risk of serious&#xD;
      bleeding without reduction in therapeutic efficacy in this very elderly population.&#xD;
&#xD;
      Confirmation of a reduction in the risk of bleeding at this dosage could be the start of a&#xD;
      change in prescribing practices, towards a more suitable dosage in the elderly.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2021</start_date>
  <completion_date type="Anticipated">April 18, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study of the risk of bleeding in patients over 75 years of age taking Enoxaparin at a fixed curative dose of 4000 IU twice a day</measure>
    <time_frame>Files analysed retrospectively from January 01, 2000 to November 30, 2021 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Venous Thromboembolic Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        - Subjects of age&gt; = 75 years and having a weight&gt; = 45kg for women and&gt; = 57kg for men and&#xD;
        a BMI &lt;30, a GFR&gt; 30 ml / min in Cockcroft-Gault, and having benefited from treatment with&#xD;
        Enoxaparin for deep vein thrombosis and / or pulmonary embolism between 01/01/2000 to&#xD;
        11/30/2021.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Subjects of age&gt; = 75 years&#xD;
&#xD;
          -  Having a weight&gt; = 45kg for women and&gt; = 57kg for men and a BMI &lt;30, a GFR&gt; 30 ml /&#xD;
             min in Cockcroft-Gault, and having benefited from treatment with Enoxaparin for deep&#xD;
             vein thrombosis and / or pulmonary embolism between 01/01/2000 to 11/30/2021.&#xD;
&#xD;
          -  Subject having been informed by posting in the service and / or via the welcome&#xD;
             booklet and not having expressed his opposition to the reuse of his data.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Subject having expressed opposition to participating in the study&#xD;
&#xD;
          -  History of heparin-induced thrombocytopenia in the last 100 days,&#xD;
&#xD;
          -  condition associated with a high risk of bleeding such as congenital or acquired blood&#xD;
             pathology,&#xD;
&#xD;
          -  a recent hemorrhagic stroke,&#xD;
&#xD;
          -  a gastrointestinal ulcer,&#xD;
&#xD;
          -  the presence of a malignant tumor at high risk of bleeding, recent surgery of the&#xD;
             brain, spine or ophthalmology, known or suspected oesophageal varices, arteriovenous&#xD;
             malformations, a vascular aneurysm or major intraspinal or intracerebral vascular&#xD;
             anomalies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>76 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander BOUSSUGE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Gériatrie. Soins de Longue Durée - Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre BOUSSUGE, MD</last_name>
    <phone>33 3 88 11 54 61</phone>
    <email>alexandre.boussuge@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Gériatrie. Soins de Longue Durée - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander BOUSSUGE, MD</last_name>
      <phone>33 3 88 11 54 61</phone>
      <email>alexandre.boussuge@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander BOUSSUGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Pauline DEBROS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas VOGEL, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François LEFEBVRE, Statistician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombophlebitis</keyword>
  <keyword>Anticoagulant therapy</keyword>
  <keyword>Enoxaparin</keyword>
  <keyword>Venous Thromboembolic Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

